NL-OMON51156已完成2 期
A randomized, double-blind, placebo-controlled, multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19 - MP0420-CP302
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Men or women * 18 years of age on the day of inclusion (no upper limit).
- •2. Presence of two or more COVID-19 symptoms and onset within 7 days prior to
- •dosing: Feeling hot or feverish, cough, sore throat, low energy or tiredness,
- •headache, muscle or body aches, chills or shivering, and shortness of breath.
- •3. Positive test for SARS-CoV-2 in upper respiratory swab on the day of dosing
- •(rapid antigen test).
- •4. Understand and agree to comply with the planned study procedures.
- •5. The patient gives signed informed consent.
排除标准
- •1. Requiring hospitalization at time of screening, or at time of study drug
- •administration.
- •2. Oxygen saturation (SpO2) * 93% on room air at sea level or ratio of arterial
- •oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2)
- •< 300, respiratory rate * 30 per minute, and heart rate * 125 per minute.
- •3. Known allergies to any of the components used in the formulation of the
- •ensovibep or placebo.
- •4. Suspected or proven serious, active bacterial, fungal, viral, or other
- •infection (besides SARS-CoV-2) that in the opinion of the investigator could
- •constitute a risk when taking intervention.
- •5. Any serious concomitant systemic disease, condition, or disorder that, in
- •the opinion of the investigator, should preclude participation in this study.
- •6. Any co-morbidity requiring surgery within 7 days of dosing, or that is
- •considered life-threatening within 29 days of dosing.
- •7. Prior or concurrent use of any medication for treatment of COVID-19,
- •including antiviral agents, convalescent serum, or anti-viral antibodies.
- •Purely symptomatic therapies (e.g., over-the-counter [OTC] cough medications,
- •acetaminophen, and nonsteroidal anti-inflammatories [NSAIDs]) are permitted.
- •Prior vaccination for COVID-19 is permitted.
研究者
相似试验
进行中（未招募）
1 期
Study on the safety of the drug runcaciguat and how well it works when given at the highest dose as tolerated by the individual patient whose kidneys are not working properly and suffering at the same time from a disease of the heart and the blood vessels and high blood sugarTreatment of cardiovascular and renal disease in patients with chronic kidney diseaseMedDRA version: 21.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.0Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2019-003297-53-ESBayer AG432
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2500 mg/d combined with risperidone in the treatment of manic episodes of bipolar I disorder over 6 weeksBipolar I disorder, manic and mixed episodesEUCTR2004-000113-18-HUovartis Hungaria Kft.430
进行中（未招募）
1 期
Phase 2b dose-ranging study of ALX-0171 in infants and young children hospitalized for RSV lower respiratory tract infectioRSV lower respiratory tract infectionMedDRA version: 20.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-001651-49-SKAblynx NV180
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapyDiffuse Large B-Cell LymphomaMedDRA version: 19.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-000498-40-HUovartis Pharma Services AG487
进行中（未招募）
1 期
Safety and efficacy study in patients with moderate to severe nail psoriasisModerate to severe nail psoriasisMedDRA version: 18.0Level: PTClassification code 10028703Term: Nail psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2012-005413-40-BEovartis Pharma Services AG195